See what COSENTYX
can do for your patients
The first AND only
fully human monoclonal antibody
to selectively target il-17A
approved for moderate to severe plaque psoriasis,
active psoriatic arthritis, and ankylosing spondylitis
See what COSENTYX can do for your patients
The first AND only fully human monoclonal antibody to selectively target il-17A
approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and ankylosing spondylitis